SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (NASDAQ: IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018, which followed 483 eyes with glaucoma that were undergoing cataract surgery with concomitant trabecular microbypass stent insertion. The study was initially presented at the American Society of Cataract and Refractive Surgery (ASCRS) and examines post-surgery outcomes for patients receiving an intravitreal injection of steroid and antibiotics at the time of surgery compared with a standard drop regimen following surgery.
All study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of surgery in parallel with the cataract surgery procedure. The study group of 234 eyes received an intravitreal injection (pars plana) of 0.2 mL of Dropless®, a combination of steroid and antibiotics, at the time of surgery. The control group of 249 eyes received a standard topical regimen postoperatively.
To evaluate safety, the incidence of intraocular pressure (IOP) spikes was also recorded, which was defined as an increase of at least 15 mm Hg from baseline IOP. There was no statistically significant difference in the rate of IOP spikes between the two groups. The safety profiles of both groups were favorable. In the study group, there were no reported cases of inflammation, cystoid macular edema (CME), infection or retinal detachments.
Imprimis CEO, Mark L. Baum, commented, "The publication of this study of one of our Dropless® formulations in one of the most prestigious peer-reviewed ophthalmology journals validates the experiences of hundreds of thousands of patients over the past four years. This formulation continues to be an important option for patients and doctors alike, to help reduce or eliminate the need for post-surgery eye drop regimens and the potential for complications with medication adherence."
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is dedicated to making high-quality innovative medications accessible and affordable. The company's flexible business model allows a drug to be compounded or developed as an FDA-approved product through one of its subsidiaries or deconsolidated companies. For more information about Imprimis, please visit the Investor Relations section of the corporate website by clicking here.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Imprimis's Dropless® compounded formulation is not FDA-approved. Other than drugs compounded at a registered outsourcing facility, all Imprimis compounded formulations require a prescription for an individually identified patient consistent with federal and state laws.
Source: Imprimis Pharmaceuticals, Inc.
Holliday Communications, Inc.
View original content with multimedia:http://www.prnewswire.com/news-releases/imprimisrxs-dropless-steroid-and-antibiotic-intravitreal-injection-featured-in-the-prestigious-journal-of-cataract-and-refractive-surgery-300656202.html
SOURCE Imprimis Pharmaceuticals, Inc.